drugset / Trial / NCT01023737
Hydroxychloroquine + Vorinostat in Advanced Solid Tumors
Phase 1
Completed
72 enrolled
The University of Texas Health Science Center at San Antonio
Merck Sharp & Dohme LLC · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is an open label non randomized study of hydroxychloroquine (HCQ) with histone deacetylase (HDAC) inhibitor Vorinostat in patients with advanced solid tumors to determine the maximum tolerated dose (MTD) and to evaluate the safety and antitumor activity of this drug combination.
Timeline
- Start
- 2009-11
- Primary completion
- 2017-12-05
- Completion
- 2023-01-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hydroxychloroquine | Small molecule | 400 mg | Oral |
| Subject | Hydroxychloroquine | Small molecule | 600 mg | Oral |
| Subject | Hydroxychloroquine | Small molecule | 800 mg | Oral |
| Subject | Hydroxychloroquine | Small molecule | 1000 mg | Oral |
| Subject | Vorinostat | Small molecule | 300 mg | Oral |